Ezetimibe

Introduction Overview

Generic Name

ezetimibe

Brand Name

Zetia

Dosage Form

oral tablet

Drug Class

Cholesterol absorption inhibitors

Pharmacokinetics

Absorption: Ezetimibe is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours. The drug undergoes enterohepatic recirculation, which extends its presence in the circulation and contributes to sustained plasma levels. Food intake does not significantly affect its absorption, allowing administration with or without food. The absolute bioavailability of ezetimibe tablets has not been specifically quantified due to extensive first-pass metabolism.

Distribution: After absorption, ezetimibe is extensively bound to plasma proteins (>90%), primarily albumin, which limits its volume of distribution. It is widely distributed to tissues but does not significantly cross the blood-brain barrier. The drug and its active glucuronide metabolite circulate systemically, both contributing to pharmacologic effects.

Metabolism: Ezetimibe is extensively metabolized in the intestinal mucosa and liver to an active phenolic glucuronide metabolite via UDP-glucuronosyltransferase enzymes. This glucuronidation conjugate retains pharmacologic activity and is the predominant circulating form in the plasma. Minimal involvement of cytochrome P450 enzymes occurs, which reduces the risk of cytochrome-mediated drug interactions.

Elimination: Ezetimibe and its metabolites are eliminated primarily via biliary excretion into the feces, with approximately 78% of the dose recovered in feces and about 11% in urine over 10 days. The elimination half-life is approximately 22 hours, supporting once-daily dosing. The dual elimination pathways through biliary and renal routes ensure effective drug clearance. Clinical studies indicate no significant accumulation with repeated dosing.

Dosage Forms

Available Dosage Forms: Zetia is commercially available as oral tablets of 10 mg strength.

Dosages for Adults and Adolescents:
- Adults: 10 mg orally once daily, used as monotherapy or in combination with statins or fenofibrate for primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and sitosterolemia.
- Adolescents (10 years or older): Same dose of 10 mg orally once daily for hyperlipidemia management.

Specific Patient Populations: No dosage adjustments are currently recommended in elderly patients, mild to moderate renal impairment, or mild hepatic impairment. Zetia is contraindicated in patients with moderate to severe hepatic dysfunction. Pediatric use below age 10 is not approved due to lack of established safety and efficacy.

Clinical Guidelines: Administration can be with or without food, preferably at the same time daily. Concurrent use with bile acid sequestrants is discouraged within a 2-hour before to 4-hour after window due to potential absorption interference. Monitoring of liver function is advised especially when co-administered with statins, given potential hepatic adverse effects.

Mechanism Of Action

Ezetimibe selectively inhibits the absorption of cholesterol at the small intestine brush border by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transport protein, a critical mediator of cholesterol uptake into enterocytes. This inhibition decreases the delivery of intestinal cholesterol to the liver, subsequently reducing hepatic cholesterol stores. The liver responds by increasing clearance of circulating low-density lipoprotein cholesterol (LDL-C).

At the cellular level, ezetimibe acts on the brush border membranes of enterocytes, preventing the internalization of cholesterol-laden micelles. By limiting the intestinal absorption of both dietary and biliary cholesterol, ezetimibe reduces the overall cholesterol pool available for incorporation into lipoproteins.

Ezetimibe is distinct from statins, which act primarily by inhibiting hepatic HMG-CoA reductase and cholesterol synthesis. The complementary mechanism of ezetimibe renders it effective as monotherapy or synergistically in combination with statins, fenofibrates, or other agents to achieve greater LDL-C reduction.

Clinical trials and research have demonstrated that ezetimibe's unique pathway inhibition leads to significant reductions in total cholesterol, LDL-C, apolipoprotein B, and non–high-density lipoprotein cholesterol, contributing to decreased atherosclerotic cardiovascular risk when combined with lifestyle interventions.

Pharmacological Actions

Inhibits intestinal absorption of cholesterol via NPC1L1 transporter blockade
Reduces plasma total cholesterol and LDL cholesterol concentrations
Lowers apolipoprotein B and non-HDL cholesterol levels
Does not significantly affect triglycerides or HDL cholesterol as a primary effect
Exhibits synergistic lipid-lowering effects when combined with statins or fenofibrate
Does not inhibit cholesterol biosynthesis or significantly impact liver cholesterol synthesis pathways
Minimally metabolized by cytochrome P450 system reducing drug interaction risk
Results in increased clearance of LDL particles from plasma due to decreased hepatic cholesterol
Provides adjunctive therapy for homozygous familial hypercholesterolemia and sitosterolemia
Demonstrates good oral bioavailability and prolonged half-life supporting once-daily dosing

Therapeutic Or Clinical Uses

Treatment of primary (heterozygous familial and non-familial) hyperlipidemia to reduce elevated total cholesterol and LDL-C
Adjunctive therapy with statins to lower cholesterol in patients inadequately controlled on statins alone
Combination therapy with fenofibrate in mixed hyperlipidemia for additional LDL-C and Apo B reduction
Management of homozygous familial hypercholesterolemia to reduce total cholesterol and LDL-C levels
Reduction of elevated sitosterol and campesterol concentrations in patients with homozygous familial sitosterolemia
Adjunctive therapy to diet and lifestyle modifications including weight control and exercise for lipid management
Used in patients who cannot achieve adequate cholesterol control through diet and exercise alone
Improves lipid profiles to reduce cardiovascular risk associated with hypercholesterolemia
Alternative or adjunct to statin therapy in patients intolerant of higher statin doses
May be combined with LDL apheresis in severe familial hypercholesterolemia when other treatments are inadequate

Side Or Adverse Effects

Diarrhea
Upper respiratory tract symptoms including stuffy nose, sneezing, and sore throat
Myalgia (muscle pain), particularly when combined with statin therapy
Joint pain (arthralgia)
Local allergic reactions such as rash or urticaria
Rare but serious risk of muscle breakdown (rhabdomyolysis) especially in combination with statins
Potential for liver enzyme elevations and hepatotoxicity
Fatigue and weakness
Abdominal pain or discomfort
Back pain
Elevated creatine kinase levels in rare instances
Headache
Hypersensitivity reactions including angioedema and anaphylaxis (rare)
Generally well tolerated with low incidence of severe adverse effects
Rare reports of pancreatitis or thrombocytopenia

Precautions

Use only as part of a comprehensive cholesterol-lowering regimen including diet and exercise
Perform baseline and periodic liver function tests, especially when combined with statins
Monitor for muscle pain, tenderness, or weakness, which require prompt evaluation
Avoid use in patients with moderate to severe hepatic impairment
Notify healthcare providers of unexplained muscle symptoms or dark urine immediately
Exercise caution in elderly patients due to potential increased risk of adverse effects
Avoid co-administration with bile acid sequestrants within 2 hours before and 4 hours after dosing
Use effective contraception methods during coadministration with statins due to potential teratogenic risks
Adjust concomitant medications carefully to avoid drug interactions
Not approved for use in children under 10 years of age
Assess renal function as renal disease may alter drug pharmacokinetics and increase adverse effect risk
Educate patients on adherence to lifestyle modifications alongside medication use
Regular lipid and hepatic monitoring recommended to assess efficacy and safety
Discontinue medication if signs of serious liver damage or muscle injury develop
Inform patients about early symptoms of allergic reactions and muscle toxicity

Warnings

Do not use Zetia in patients with moderate to severe liver disease
Avoid use with statins in patients with active liver disease or during pregnancy and breastfeeding
Risk of muscle toxicity increases when combined with statins, especially in elderly or renal impaired
Stop drug if unexplained muscle pain, tenderness, weakness, fever, or dark urine occur
Zetia efficacy depends on concomitant adherence to cholesterol-lowering diet and lifestyle
Concurrent cholesterol medications may require careful dosing and timing to avoid interactions
Pregnant or breastfeeding women should avoid Zetia especially when combined with statins
Monitor liver enzymes periodically as hepatotoxicity, although rare, has been reported
Use with caution in patients with hypothyroidism or pre-existing renal dysfunction
Do not exceed recommended dose to prevent increased adverse reaction risk
Inform patients about the potential delayed onset of cholesterol-lowering effects (up to 2 weeks)
Avoid concomitant use with bile acid sequestrants without appropriate spacing of doses
Immediate medical attention required if symptoms of hypersensitivity or severe adverse reactions develop
Patients should not double dose if a dose is missed; skip and take next scheduled dose
Zetia is not a substitute for lifestyle modifications and should not be used as monotherapy without appropriate dietary control

Contraindication

Hypersensitivity to ezetimibe or any component of the formulation
Moderate to severe hepatic impairment
Active liver disease
Pregnancy when used in combination with statins
Breastfeeding when used with statins
Use in pediatric patients under 10 years of age due to lack of safety data
Concomitant use with statins contraindicated in patients with active liver disease
Known hypersensitivity reactions including anaphylaxis to previous ezetimibe treatment
Use is contraindicated without proper dietary cholesterol-lowering measures
Caution against use with drugs that significantly interact and alter ezetimibe plasma levels
Contraindicated if patient has unexplained persistent muscle symptoms and elevated CK with previous therapy
Concurrent use with bile acid sequestrants without dose separation is contraindicated
Contraindicated where patient compliance to monitoring and lifestyle is not feasible
Patients with severe renal impairment require careful assessment before initiation

Drug Interactions

Bile acid sequestrants (cholestyramine, colestipol, colesevelam) reduce ezetimibe absorption; separate dosing by at least 2 hours before or 4 hours after
Increased plasma concentrations with cyclosporine due to altered hepatic metabolism and excretion
Fenofibric acid and gemfibrozil may increase risk of muscle toxicity when combined with ezetimibe
Concomitant use with warfarin may enhance anticoagulant effect; requires close monitoring of INR and bleeding
No significant cytochrome P450 mediated interactions due to minimal CYP involvement
Potential additive muscle toxicity when combined with statins (atorvastatin, simvastatin, lovastatin, pravastatin, fluvastatin)
Drugs that affect hepatic glucuronidation may affect ezetimibe metabolism
Minimal interaction with other drugs, but caution advised with polypharmacy especially in elderly
No significant interaction with antihypertensive, diabetic, or common cardiovascular drugs observed
Monitoring needed when initiating or discontinuing interacting drugs to avoid adverse effects
Herbal supplements and vitamins do not have documented interactions but should be reported to clinician
Concomitant use with fibrates may increase risk of cholelithiasis; monitoring recommended
Drug interactions affecting plasma protein binding are unlikely to be clinically relevant
Adjustments of anticoagulant therapy may be required during co-administration
Advisable to inform healthcare provider about all medications to manage potential interactions

Preparations Of The Drug

Oral tablets containing 10 mg ezetimibe
Generic formulations available as 10 mg film-coated tablets
Fixed-dose combination tablets available containing ezetimibe with simvastatin
Single-agent oral tablets intended for once daily administration
Commercial packaging commonly available in blister packs or bottles
Formulated for stable oral bioavailability and convenient patient dosing
Storage recommended at controlled room temperature, protected from moisture and heat
No injectable or alternative dosage forms currently marketed
Combination products aim to improve adherence by reducing pill burden
Tablets strength uniform for adults and adolescents 10 years and above
Non-prescription or OTC forms are not available; prescription only
Pharmaceutical grade ezetimibe manufactured in compliance with GMP standards
Some generic versions manufactured with excipients tailored to improve patient tolerability
Manufacturers may provide patient information leaflets detailing administration and storage
Packaging labeled with clear dosage and administration guidance for patient safety